Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients
To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer duration, in attempt to improve patients quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Agustin Avil ès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri Tags: Original Study Source Type: research

Thoracic Complications in Chronic Lymphocytic Leukemia (Thoracic Diseases in CLL)
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia. Patients with CLL often present with pulmonary symptoms and diagnoses. We performed a retrospective, single center, chart review evaluating all patients with CLL admitted with a thoracic symptom or diagnosis. Although pneumonia is frequent, there are an increasing number of non-infectious complications, which often require lower respiratory tract sampling. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Sameer Khanijo, Pragati Tandon, Cristina P. Sison, Seth Koenig Tags: Original Study Source Type: research

Clinical features and prognosis analysis of Hodgkin ’s lymphoma: A multicenter retrospective study over a decade of patients in China
Little information of Hodgkin ’s lymphoma (HL) is available in Chinese patients. We analyzed their clinical features, outcome and prognostic factors aiming to establish a new risk model for better risk-adapted therapeutic strategy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Wen-Yan yu, Mei Geng, Jie Hao, Mei Chen, Su-Jiang Zhang, Jin Wang, Jian-Qing Mi Tags: Original Study Source Type: research

Whole Body MR imaging: A Useful Imaging Modality in the Management of Children with Acute Myeloid Leukemia
Children with acute myeloid leukemia suffer from various complications such as chloromas and disseminated infection or inflammation during their illness. As these complications tend to involve everywhere in the body, whole body MR imaging may be a useful tool in children with acute myeloid leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Hee Mang Yoon, Jeong Rye Kim, Ah Young Jung, Young Ah Cho, Ho Joon Im, Jin Seong Lee Tags: Original Study Source Type: research

Systemic Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival
We used the SEER database to study the incidence and survival of ALK positive ALCL. We found that the disease incidence varied significantly by age, gender and race, while survival was influenced by age, race, stage, period of diagnosis and radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Mehdi Hamadani, Vijaya Raj Bhatt, Ishwori Dhakal, Paulette Mehta Tags: Original Study Source Type: research

The efficacy of generic imatinib as first- and second-line therapy: three year follow-up of chronic myeloid leukemia patients
We examined the long-term clinical outcomes of CML patients (n=41) receiving generic imatinib as first-line (n=27) and second-line therapy (n=14) in Bosnia and Herzegovina. OS rates for first-line and second-line generic imatinib were 85% vs. 100%, respectively. For first-line generic imatinib, CCyR was 81%. Generic imatinib as second-line therapy does not have deleterious effects on patient outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 15, 2017 Category: Hematology Authors: Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric, Amina Kurtovic-Kozaric Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2017 Category: Hematology Source Type: research

The Society of Hematologic Oncology (SOHO): Continuing to Move Forward in the Battle against Hematologic Malignancies
The Society of Hematologic Oncology (SOHO) is an international society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO ’s mission is to promote worldwide research and education through the exchange of scientific information. Organized by its founders and world class committees, SOHO is the only international society specific to this field. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 17, 2017 Category: Hematology Authors: Hagop Kantarjian Tags: Editorial Source Type: research

Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy
With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with acute myeloid leukemia (AML) have access to allo-SCT and mortality has decreased.1 However, 30%-40% of patients relapse, outcome after post-transplant relapse is poor, and most patients do not benefit from salvage chemotherapy. Approximately one-third of these patients harbor Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), which is associated with sensitivity to several tyrosine kinase inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey Tags: Letter to the Editor Source Type: research

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
The purpose of our study was to identify risk factors for the development of posterior reversible encephalopathy syndrome (PRES) after administration of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH). Of 44 patients receiving DA-EPOCH at our institution, 3 (7%) developed PRES. The patients who developed PRES were more likely to have a pre-existing central nervous system insult, fluid status or electrolytes abnormalities, and hypertension. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research

Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients
The aim of the present study was to test the possibility for the usage of the WT1 (Wilms tumor 1) expression level as an additional biomarker for prognosis and minimal residual disease (MRD) monitoring in patients with acute myeloid leukemia with normal karyotype (AML-NK). We found that overexpression of WT1 had a negative effect on treatment outcome. It was a suitable marker for MRD monitoring and a marker for refined risk stratification of AML-NK patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Irena Marjanovic, Teodora Karan-Djurasevic, Milena Ugrin, Marijana Virijevic, Ana Vidovic, Dragica Tomin, Nada Suvajdzic Vukovic, Sonja Pavlovic, Natasa Tosic Tags: Original Study Source Type: research

Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE extranodal nasal type NK/T cell lymphoma : a study of two centers
At present, various L-asparaginase-based regimens were used to treat stage IIE extranodal nasal type NK/T cell lymphoma (ENKTL). This retrospective study analyzed the data of 80 patients to evaluate the efficacy of a new L-asparaginase-based LOP regimen + radiotherapy (RT) protocol over classic CHOP + RT protocol in Guizhou province of China. It shows that protocol is a safe alternative to other protocols reported in the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Limin Huang, Bin Yuan, Haixia Wu, Hongliang Chu, Yayun Liu, Shuang Wu, Hong Li, He Lu, Hui Chen Tags: Original Study Source Type: research

Treatment of post transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy
With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with Acute Myeloid Leukemia (AML) access to allo-SCT and mortality has decreased1. However, 30-40% of patients relapse, outcome after post-transplant relapse is poor and most patients do not benefit from salvage chemotherapy. Approximately one third of these patients harbor FLT3 internal tandem duplication (FLT3-ITD) which is associated with sensitivity to several Tyrosine Kinase Inhibitors (TKI). Sorafenib is a multikinase inhibitor targeting FLT3 and the Raf/ERK/MAP kinase pathway with single agent clinical activity in FLT3 mutated ...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Selim Sid, Rey Jerome, Charbonnier Aude, D ’Incan Evelyne, Mohty Bilal, Blaise Didier, Norbert Vey Tags: Letter to the Editor Source Type: research

Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy
The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) following administration of DA-EPOCH. Out of 44 patients receiving DA-EPOCH at our institution, 3 (7%) were diagnosed with PRES. Patients who developed PRES were more likely to have a preexisting CNS insult, fluid status or electrolytes abnormalities, and hypertension. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research

Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)
Hypomethylating agents (HMA) remain the mainstay of treatment in patients with Myelodysplastic Syndrome (MDS). Azacitidine (AZA) is the only agent shown to improve overall survival in higher risk MDS. Sequential use of HMA is a common practice given limited alternatives. The response rate to AZA after Decitabine (DAC) is unknown. To investigate the potential benefit of this approach, we reviewed all cases of sequential HMA treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Susmitha Apuri, Najla Al Ali, Eric Padron, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji Tags: Original Study Source Type: research

Usage of Wilms ’ Tumor 1 (WT1) Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Normal Karyotype (AML-NK) Patients
The aim of this study was to test the possibility for the usage of WT1 expression level as an additional biomarker for prognosis and minimal-residual-disease (MRD) monitoring in AML-NK patients. We found that overexpression of WT1 had negative impact on treatment outcome. It was a suitable marker for MRD monitoring, and marker for refined risk stratification of AML-NK patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Irena Marjanovic, Teodora Karan-Djurasevic, Milena Ugrin, Marijana Virijevic, Ana Vidovic, Dragica Tomin, Nada Suvajdzic Vukovic, Sonja Pavlovic, Natasa Tosic Tags: Original Study Source Type: research

Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study
To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Tomasz Sacha, Joanna G óra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław, Andrzej Hellmann Tags: Original Study Source Type: research

More about the risk of Ibrutinib-associated bleeding
Sir (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Ambra Paolini, Valeria Coluccio, Mario Luppi, Marco Marietta Tags: Letter to the Editor Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 31, 2016 Category: Hematology Source Type: research

Myeloma in the Real World: What Is Really Happening?
Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. (Source: Clinical Lymph...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Tags: Review Source Type: research

Prognostic Implications of Monosomies in Patients with Multiple Myeloma
This study evaluated the prevalence and prognostic implications of monosomies in 170 Korean patients with multiple myeloma (MM). Monosomies in chromosomes 16, chromosomes 13, TP53 (17p) deletion, and hypodiploidy had adverse prognostic implications in patients with MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Sang-Yong Shin, Hyeon-Seok Eom, Ji Yeon Sohn, Hyewon Lee, Boram Park, Jungnam Joo, Ja-Hyun Jang, Mi-Na Lee, Jung Kwon Kim, Sun-Young Kong Tags: Original Study Source Type: research

Myeloma in the Real World: What ’s really happening?
Multiple myeloma (MM) is the second most common haematological malignancy and predominantly a disease of the elderly. In the last two decades a range of new therapeutic options have become available leading to improvements in patient outcomes including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach towards more active management including use of sequential therapies, with the goal to prolong progression-free and overall survival, while preserving organ function to enable delivery of further therapy at relapse. (Source: Clinical Lymphoma, ...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Tags: Review Article Source Type: research

Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma
Immune cell subsets in the blood of patients with diffuse large B-cell lymphoma before therapy were characterized by flow cytometry, and the levels of various T-cell types and natural killer cells were correlated with the eventual outcomes. High absolute levels of CD4 cells in the blood correlated with better progression-free survival and, to a lesser extent, overall survival, independent of patient age and International Prognostic Index score. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 28, 2016 Category: Hematology Authors: Julia Judd, Essel Dulaimi, Tianyu Li, Michael M. Millenson, Hossein Borghaei, Mitchell R. Smith, Tahseen Al-Saleem Tags: Original Study Source Type: research

Low Level of Blood CD4+ T-Cells Is An Independent Predictor of Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma
Immune cell subsets in blood of patients with diffuse large B cell lymphoma prior to therapy were characterized by flow cytometry and levels of various T-cell types and NK cells correlated with eventual outcomes. High absolute levels of CD4 cells in blood correlated with better progression free survival, and to a lesser extent overall survival, independent of age and IPI. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 28, 2016 Category: Hematology Authors: Julia Judd, Essel Dulaimi, Tianyu Li, Michael M. Millenson, Hossein Borghaei, Mitchell R. Smith, Tahseen Al-Saleem Tags: Original Study Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age
Autologous hematopoietic cell transplantation has been shown to prolong survival in patients with multiple myeloma; however, adequate data are lacking for patients aged> 70 years and   70 vs.  ≤ 50 years). Our study showed comparable outcomes between these 2 age groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Authors: Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D'Souza, Parameswaran Hari Tags: Original Study Source Type: research

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age
Autologous hematopoietic cell transplantation (AHCT) has been shown to prolong survival in patients with multiple myeloma (MM), however adequate data is lacking in patients>70 years and less than 50 years of age. We retrospectively analyzed and compared the outcome of patients between the two age groups (>70 vs. ≤ 50 yrs.). Our study showed comparable outcomes between these two age groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Authors: Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D ’Souza, Parameswaran Hari Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 23, 2016 Category: Hematology Source Type: research

Acute Leukemia of Ambiguous Lineage in Elderly Patients – Analysis of Survival using Surveillance Epidemiology and End Results-Medicare Database
We used the SEER-Medicare database to study the overall survival and treatment pattern of elderly patients with acute leukemia of ambiguous lineage in United States. Overall survival of this leukemia remains poor, but is improved significantly with chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2016 Category: Hematology Authors: Guru Subramanian Guru Murthy, Ishwori Dhakal, Jeanette Y. Lee, Paulette Mehta Tags: Original Study Source Type: research

Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
The standard of care for diffuse large B-cell lymphoma (DLBCL) relapsing after front-line therapy is high-dose chemotherapy and autologous stem cell transplantation (ASCT). Patients with relapsed or refractory DLBCL experiencing relapse> 1 year after ASCT had good outcomes. Despite the relative rarity in incidence, a significant risk of relapse of DLBCL after ASCT remains, suggesting the need for continued monitoring because of the possibility of later progression. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis S. Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo Tags: Original Study Source Type: research

Late Relapses following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era
The standard of care for diffuse large B cell lymphoma (DLBCL) relapsing after front line therapy is high dose chemotherapy and autologous stem cell transplant (ASCT). Evidence suggests that early relapses (i.e. within 1 year) following this approach portends exceptionally poor outcomes. However, there are limited data examining relapses>1 year after ASCT for patients with refractory or relapsed DLBCL, particularly in the rituximab era. We sought to examine the impact of early ( ≤1 year) and late (>1 year) relapse following ASCT in a single-institution cohort of patients with relapsed and refractory DLBCL treated ...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo Tags: Original Study Source Type: research

Practical Considerations in Managing Relapsed Multiple Myeloma
Considerable advances have been made in the treatment of relapsed and relapsed/refractory multiple myeloma (RRMM), with numerous novel agents and combination strategies receiving regulatory approvals worldwide over the last several years. An increasing body of phase III data clearly demonstrates increased overall response rates, improved depths of response and more durable responses when a third novel agent is incorporated into Lenalidomide-Dexamethasone and Bortezomib-Dexamethasone platforms, in most cases with acceptable toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Amit Agarwal, Eric Chow, Manisha Bhutani, Peter M. Voorhees, Reed Friend, Saad. Z. Usmani Tags: Review Article Source Type: research

Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis
Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We show that the hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. The combination of tyrosine kinase inhibitors for Philadelphia chromosome-positive (+) patients and rituximab for CD20+ patients were significantly more frequent in the hyper-CVAD arm and might have affected outcomes favorably. There is still a need for large, prospective, randomized studies to establish the best...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Jean El-Cheikh, Imane El Dika, Radwan Massoud, Maya Charafeddine, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi Tags: Original Study Source Type: research

Improving Survival of Patients With Hodgkin Lymphoma Over 4 Decades: Experience of the British National Lymphoma Investigation (BNLI) With 6834 Patients
Survival for Hodgkin lymphoma has improved over the last 4 decades thanks to reducing the risks of death from primary disease and, expectantly, treatment-related toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Amy Kwan, Nick Chadwick, Barry Hancock Tags: Original Study Source Type: research

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study
The present study provides a unique look at real world cardiac event rates for a large group of multiple myeloma (MM) patients treated with selected anti-MM treatments. The cardiac event risk for any cardiac event, including hypertensive or arterial events, cardiac dysrhythmias, congestive heart failure, ischemic heart disease, cardiomyopathy, and conduction disorders, was greater in MM patients with  ≥ 3 previous drugs (n = 1723) compared with patients without MM (n = 8615). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Kristin D. Kistler, Jill Kalman, Gagan Sahni, Brian Murphy, Winifred Werther, Kanya Rajangam, Ajai Chari Tags: Original Study Source Type: research

Hyper-CVAD compared to BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective single center analysis
Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We demonstrate that the hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Addition of TKI for Ph+ cases and rituximab for CD20+ cases were significantly more frequent in the Hyper-CVAD arm and may have affected outcomes favorably. There is still a need for large, prospective, randomized studies in order to establish the best induction regimen for adult ALL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Jean El Cheikh, Imane El Dika, Radwan Massoud, Maya Charafeddine, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi Tags: Original Study Source Type: research

A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome
Management of tumor lysis syndrome (TLS), a potentially fatal oncologic complication following initiation of chemotherapy or other cytotoxic treatment or occurring spontaneously before treatment, has significant economic impact. This retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clinical TLS found that patients treated with rasburicase, compared with those receiving allopurinol, had significantly greater mean reduction in UA levels, significantly lower ICU and overall hospital length of stay, and lower total hospitalization costs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Mitchell S. Cairo, Stephen Thompson, Krishna Tangirala, Michael T. Eaddy Tags: Original Study Source Type: research

The Improving Survival of Patients with Hodgkin Lymphoma Over Four Decades – Experience of the British National Lymphoma Investigation (BNLI) with 6834 Patients
The management of Hodgkin lymphoma has changed markedly over the last 50 years. This is due to the expanding understanding about the biology of the disease, the development of increasingly efficacious multi-modality treatment and the recognition of how to reduce late effects. The BNLI was formed in the 1970s to co-ordinate UK research in the diagnosis and treatment of lymphoma. This paper describes the improvement in trial patient survival over four decades. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Amy Kwan, Nick Chadwick, Barry Hancock Tags: Original Study Source Type: research

Change in IGHV Mutational Status of CLL Suggests Origin from Multiple Clones
Current clinical CLL grading systems poorly predict overall survival and disease aggressiveness, especially in early stage patients. (1) Among the independent molecular-based CLL prognostic markers, interphase fluorescence in-situ hybridization (FISH) DNA analysis and immunoglobulin variable region heavy chain (IGHV) mutational status are the most predictive. (2, 3) There is growing evidence that compared to FISH analysis, IGHV mutational sequence status better discriminates for overall survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Afaf Osman, Christopher D. Gocke, Douglas E. Gladstone Tags: Original Study Source Type: research

The incidence and risk of cardiac events in patients with previously treated multiple myeloma vs. matched patients without multiple myeloma: an observational, retrospective, cohort study
This study provides a unique look at real world cardiac event rates for a large group of MM patients treated with selected anti-myeloma treatments. Cardiac event risk for any cardiac event including hypertensive/arterial events, cardiac dysrhythmias, CHF, IHD, cardiomyopathy, and conduction disorders was greater in MM patients with ≥3 prior drugs (n=1,723) compared to patients without MM (n=8,615). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Kristin D. Kistler, Jill Kalman, Gagan Sahni, Brian Murphy, Winifred Werther, Kanya Rajangam, Ajai Chari Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 31, 2016 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2016 Category: Hematology Source Type: research

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: a Systematic Review and Pooled-Analysis of Four Randomized Controlled Trials
The goal of the present study was to precisely assess the risk of Atrial fibrillation/flutter (Afib/Aflutter) and bleeding associated with ibrutinib compared to other treatments. The risks of Afib/Aflutter and all-grade bleeding were significantly higher in the ibrutinib group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2016 Category: Hematology Authors: Seongseok Yun, Nicole D. Vincelette, Utkarsh Acharya, Ivo Abraham Tags: Original Study Source Type: research

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
We reviewed 55 patients diagnosed of primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96,4% correspond to non-Hodgkin lymphoma. Results on 5-year PFS and OS were 73% and 76% respectively. Current treatments achieve good control of the disease, with an OS of 5 years in 80% of the patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2016 Category: Hematology Authors: F. Franco, J. Lavernia, D. Aguiar-Bujanda, J. Miram ón, J. Gumá, R. Álvarez, J. Gómez-Codina, F. García Arroyo, M. Llanos, M. Marin Vera, J. Alfaro, C. Quero, M. Delgado, E. Nogales, F. Menarguez, M. Martinez, M. Torrente, M. Royuela, D. Abreu, M. Pr Tags: Original Study Source Type: research

Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management
Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2016 Category: Hematology Authors: Jorge E. Cortes, Carlos A. Jimenez, Michael J. Mauro, Alex Geyer, Javier Pinilla-Ibarz, B. Douglas Smith Tags: Review Article Source Type: research

Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia
Studies on the outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (age, 19-30 years) and pediatric (age, 0-18 years) patients with AML and APL using the Surveillance, Epidemiology, and End Results-18 registry. AYA patients with AML have worse early mortality and overall survival compared with pediatric patients with AML, whereas AYA and pediatric patients with APL have similar outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Syed Sameer Nasir, Smith Giri, Sara Nunnery, Mike G. Martin Tags: Original Study Source Type: research